Experts call for the whole process of cardiovascular disease management, antihypertensive and multi-organ protection

Dozens of cardiovascular experts from all over the country jointly conducted cardiovascular health consultation activities.　Photo courtesy of cardiovascular branch of The Chinese Medical Association

Zhongxin Online, December 16 (Reporter Chen Jing) Hypertension is one of the common high-risk factors that cause cardiovascular and cerebrovascular adverse events and even death. Professor Dai Cuilian of the Affiliated Cardiovascular Disease Hospital of Xiamen University called on patients to carry out full disease management of cardiovascular diseases in an online interview with China News Network on the 16th, that is, the whole process of disease management from hypertension, a high-risk factor in the early stage of cardiovascular disease to heart failure at the end of cardiovascular disease, so as to reduce blood pressure and protect at the same time.

Dai Cuilian said: Winter is the high incidence of hypertension season, blood pressure suddenly high and low, difficult to control, coupled with many hypertension patients with a variety of chronic diseases, winter at the same time to take a variety of drugs, blood pressure values will also have a certain impact. The expert stressed that patients must not adjust the drug or stop the drug without authorization; at the same time, on the basis of blood pressure reduction, we should pay more attention to the damage of the disease to the heart, brain, kidney and other organs, so as to reduce blood pressure and protect at the same time.

Professor Dai Cuilian said: "In terms of innovative drugs, sakuba tridriasartan, which covers the whole process from hypertension to heart failure, can reduce blood pressure while protecting organs such as heart, kidneys and blood vessels, thereby blocking the cardiovascular event chain in multiple ways. It is reported that the drug has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2021)", benefiting more Chinese people.

On the same day, at the 23rd National Cardiovascular Annual Meeting of the Chinese Medical Association sponsored by the Chinese Medical Association and the Cardiovascular Branch of the Chinese Medical Association, many experts suggested that patients use the innovative intelligent disease management platform for convenient long-term management. According to reports, the artificial intelligence disease management platform for the full-line management of cardiovascular diseases - "Little Love for the Heart", relying on WeChat Mini Program as the carrier, with daily indicator monitoring, health status assessment, personalized information and other core functions, to help cardiovascular disease patients achieve more intimate and convenient disease self-management, reduce the heavy burden caused by repeated admissions.

It is understood that as a non-hospital chronic disease management project of China's heart failure, the intelligent management platform "Little Love of the Heart" was officially launched in July 2020 to help patients with heart failure to achieve self-management of out-of-hospital diseases and enhance disease awareness and management awareness. In 2021, the "Little Love for the Heart" will be comprehensively upgraded, expanding the management field from heart failure to the whole line of cardiovascular, providing one-stop service for personalized disease management for the majority of cardiovascular patients, further strengthening cardiovascular health education, and promoting the rapid development of digital chronic disease management. At present, the platform has reached more than 200,000 patients with cardiovascular diseases.

Dai Cuilian said that through the application of artificial intelligence technology, "Care for the Heart" exerts the power of digitalization, opens up the barrier of hospital management and home management, effectively benefits a wider range of patient groups, and helps them manage cardiovascular health and improve prognosis throughout the process. (End)